Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-022658
Filing Date
2025-05-06
Accepted
2025-05-06 16:03:08
Documents
84
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bcrx-20250331.htm   iXBRL 10-Q 1387380
2 EX-10.1 bcrx-20250331xex101.htm EX-10.1 33109
3 EX-10.2 bcrx-20250331xex102.htm EX-10.2 68516
4 EX-10.3 bcrx-20250331xex103.htm EX-10.3 23006
5 EX-31.1 bcrx-20250331xex311.htm EX-31.1 11109
6 EX-32.1 bcrx-20250331xex321.htm EX-32.1 4686
  Complete submission text file 0001628280-25-022658.txt   8013686

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcrx-20250331.xsd EX-101.SCH 61494
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bcrx-20250331_cal.xml EX-101.CAL 75500
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bcrx-20250331_def.xml EX-101.DEF 254612
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcrx-20250331_lab.xml EX-101.LAB 741042
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcrx-20250331_pre.xml EX-101.PRE 505751
86 EXTRACTED XBRL INSTANCE DOCUMENT bcrx-20250331_htm.xml XML 1029444
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-23186 | Film No.: 25917125
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)